- Home
- NBIX vs CHWY Comparison
NBIX vs CHWY Comparison
Compare NBIX & CHWY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBIX
- CHWY
- Stock Information
- Founded
- NBIX 1992
- CHWY 2010
- Country
- NBIX United States
- CHWY United States
- Employees
- NBIX N/A
- CHWY N/A
- Industry
- NBIX Biotechnology: Biological Products (No Diagnostic Substances)
- CHWY Catalog/Specialty Distribution
- Sector
- NBIX Health Care
- CHWY Consumer Discretionary
- Exchange
- NBIX Nasdaq
- CHWY Nasdaq
- Market Cap
- NBIX 14.4B
- CHWY 16.5B
- IPO Year
- NBIX 1996
- CHWY 2019
- Fundamental
- Price
- NBIX $150.87
- CHWY $33.70
- Analyst Decision
- NBIX Strong Buy
- CHWY Strong Buy
- Analyst Count
- NBIX 18
- CHWY 25
- Target Price
- NBIX $172.06
- CHWY $45.17
- AVG Volume (30 Days)
- NBIX 1.0M
- CHWY 6.5M
- Earning Date
- NBIX 10-28-2025
- CHWY 12-03-2025
- Dividend Yield
- NBIX N/A
- CHWY N/A
- EPS Growth
- NBIX 12.44
- CHWY N/A
- EPS
- NBIX 4.19
- CHWY 0.35
- Revenue
- NBIX $2,682,700,000.00
- CHWY $12,345,235,000.00
- Revenue This Year
- NBIX $23.68
- CHWY $8.72
- Revenue Next Year
- NBIX $18.02
- CHWY $7.87
- P/E Ratio
- NBIX $35.78
- CHWY $96.48
- Revenue Growth
- NBIX 19.61
- CHWY 9.17
- 52 Week Low
- NBIX $84.23
- CHWY $29.25
- 52 Week High
- NBIX $157.67
- CHWY $48.62
- Technical
- Relative Strength Index (RSI)
- NBIX 59.16
- CHWY 38.72
- Support Level
- NBIX $133.62
- CHWY $31.76
- Resistance Level
- NBIX $157.67
- CHWY $33.88
- Average True Range (ATR)
- NBIX 4.58
- CHWY 1.11
- MACD
- NBIX 0.98
- CHWY -0.14
- Stochastic Oscillator
- NBIX 67.98
- CHWY 34.29
About NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
About CHWY Chewy Inc.
Chewy is the largest e-commerce petcare retailer in the US, generating $11.9 billion in fiscal 2024 sales across pet food, treats, hard goods, and pharmacy categories. The firm was founded in 2011, acquired by PetSmart in 2017, and tapped public markets as a stand-alone company in 2019 after spending a couple of years developing under the aegis of the pet superstore chain. The firm generates sales from pet food, treats, over-the-counter medications, medical prescription fulfillment, and hard goods like crates, leashes, and bowls.